13. NMA results for PFS (MSKCC favourable risk group).

Results of network meta‐analysis for outcome progression‐free survival (MSKCC favourable risk group). Treatments are ordered by P‐Score (descending). Only subnetworks with >1 designs. Upper triangle: direct estimate. Lower triangle: network estimate. Subnet 1 No. of studies: 7. No. of pairwise comparisons: 7. No. of treatments: 6. No. of designs: 5 Heterogeneity/Inconsistency: Q = 6.16, df = 2, P = 0.046; I² = 67.6%, Tau² = 0.3473 Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
LEN+PEM	.		0.36 [0.11, 1.23]	.		.	.
0.80 [0.14, 4.54]	LEN+EVE		0.45 [0.13, 1.53]	.		.	.
0.36 [0.11, 1.23]	0.45 [0.13, 1.53]		SUN	.		0.59 [0.23, 1.55]	0.50 [0.19, 1.33]
0.28 [0.04, 2.10]	0.35 [0.05, 2.61]		0.79 [0.16, 3.81]	AXI		.	0.64 [0.18, 2.23]
0.21 [0.04, 1.02]	0.27 [0.06, 1.26]		0.59 [0.23, 1.55]	0.75 [0.12, 4.78]		EVE	.
0.18 [0.04, 0.87]	0.23 [0.05, 1.08]		0.50 [0.19, 1.33]	0.64 [0.18, 2.23]		0.85 [0.22, 3.32]	SOR
Subnet 2 No. of studies: 2. No. of pairwise comparisons: 2. No. of treatments: 3. No. of designs: 2 Heterogeneity/Inconsistency: Q = 0.0, df=0, P = n.a.; I² = n.a., Tau² = n.a. Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
IFN+BEV		0.83 [0.59, 1.18]			0.60 [0.42, 0.85]
0.83 [0.59, 1.18]		TEM+BEV			.
0.60 [0.42, 0.85]		0.72 [0.44, 1.18]			IFN+PLA